Non-channel functions of connexins in cell growth and cell death  by Vinken, Mathieu et al.
Biochimica et Biophysica Acta 1818 (2012) 2002–2008
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamemReview
Non-channel functions of connexins in cell growth and cell death☆
Mathieu Vinken a,⁎,1, Elke Decrock b,2, Luc Leybaert b, Geert Bultynck c, Bernard Himpens c,
Tamara Vanhaecke a, Vera Rogiers a
a Department of Toxicology-Center for Pharmaceutical Research, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium
b Department of Basic Medical Sciences-Physiology group, Faculty of Medicine and Health Sciences, Universiteit Gent, De Pintelaan 185, B-9000 Ghent, Belgium
c Department of Molecular Cell Biology-Laboratory of Molecular and Cellular Signalling, Faculty of Medicine, Katholieke Universiteit Leuven, Campus Gasthuisberg O/N-1 bus 802,
Herestraat 49, B-3000 Leuven, BelgiumAbbreviations: ASK1, apoptosis signal-regulating ki
connective tissue growth factor and nephroblastoma
Dlgh1, Discs-Large homolog 1; GJIC, gap junctional inter
nephroblastoma overexpressed; Wnt, Wingless-Int; Z
ZONAB, ZO-1-associated nucleic acid binding protein
☆ This article is part of a Special Issue entitled: T
composition, structure and characteristics.
⁎ Corresponding author. Tel.: +32 2 477 45 87; fax:
E-mail address: mvinken@vub.ac.be (M. Vinken).
1 M.V. is a postdoctoral research fellow of the Fund f
(FWO-Vlaanderen), Belgium.
2 E.D. is a doctoral research fellow of the Fund for Scie
Vlaanderen), Belgium.
0005-2736/$ – see front matter. Crown Copyright © 20
doi:10.1016/j.bbamem.2011.06.011a b s t r a c ta r t i c l e i n f oArticle history:
Received 18 April 2011
Received in revised form 8 June 2011
Accepted 15 June 2011




Cell deathCellular communication mediated by gap junction channels and hemichannels, both composed of connexin
proteins, constitutes two acknowledged regulatory platforms in the accomplishment of tissue homeostasis. In
recent years, an abundance of reports has been published indicating functions for connexin proteins in the
control of the cellular life cycle that occur independently of their channel activities. This has yet been most
exempliﬁed in the context of cell growth and cell death, and is therefore as such addressed in the current
paper. Speciﬁc attention is hereby paid to the molecular mechanisms that underpin the cellular non-channel
roles of connexin proteins, namely the alteration of the expression of tissue homeostasis determinants and the
physical interaction with cell growth and cell death regulators. This article is part of a Special Issue entitled:
The Communicating junctions, composition, structure and characteristics.
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A well-orchestrated interplay between extracellular, intracellular
and intercellular signalling networks is a prerequisite for the
maintenance of tissue homeostasis. Direct intercellular communica-
tion is mainly mediated by gap junctions. These communicating cell
junctions arise from the docking of two hemichannels of adjacent
cells, which are composed of six connexin (Cx) subunits [1–5]. Gap
junctional intercellular communication (GJIC) denotes the passivehts reserved.
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[6,7]. Numerous physiological processes, including cell growth and cell
death, are driven by the substances that are conveyed via these
channels. Hence, GJIC is considered as a key mechanism in the
regulation of tissue homeostasis [3–5,7]. In the last decade, it has
become clear that hemichannels in non-junctional areas at the plasma
membrane surface can also function as transmembrane channels,
thereby establishing a pathway for communication between the
intracellular compartment and the extracellular environment. Since
the substances that traverse throughhemichannels are similar to those
implied in GJIC, hemichannel-dependent signalling is nowadays
equally envisaged as a critical determinant of tissue homeostasis
[2,7–10]. In addition, several studies have shown that connexin
proteins as such can inﬂuence tissue homeostasis by actions that are
not related to their channel-forming capabilities [1,11–13]. These
atypical functions of connexins are discussed in the present paper,
whereby themain focus is put on their relevance in cell growth and cell
death control. At least two mechanisms underlie the non-channel
actions of connexins in the management of the cellular life cycle,
namely the modulation of the expression of tissue homeostasis
gatekeepers and the interaction with cell growth and cell death
regulators. An overview of both mechanisms is provided in the
following sections.
2. Connexin-mediated modulation of cell growth and cell death
regulator expression
Channel-independent functions of connexins in cell growth and cell
death have been frequently unveiled through genetic approaches
targeted towards the overexpression or ablation of connexin production
[14–43]. For instance, microarray analysis of heart tissue from Cx43
knock-out mice and Cx43-null mouse astrocytes showed altered
expression of a wide spectrum of apoptotic genes, including those
coding for Bcl-xL, Bok, Bax, Bid, Diablo, caspase 6 and caspase 9 [44,45].
In linewith suchobservations is the fact that connexinproteins, as single
entities, can affect the production or the activity of tissue homeostasis
regulators, including p27Kip1, cyclin A, cyclin D1, cyclin D2, cyclin-
dependent kinase 5/6, extracellular regulated kinase 1/2, signal
transducer and activator of transcription protein 3, Src, human
epidermal growth factor receptor 2, ﬁbroblast growth factor 1 and
ﬁbroblast growth factor receptor3,whichmay [32–35,42,46–53] ormay
not [19–21,24,32–36,54,55] be related to the establishment of GJIC. A
most representative study in this context is the work of Zhang and
colleagues. They showed that overexpressionof Cx43 triggers aG1/S cell
cycle arrest in human osteosarcoma cells, which is accompanied by
accumulation of hypophosphorylated retinoblastoma, a drop in cyclin-
dependent kinase 2/4 activities and elevated p27Kip1 expression. The
latter is, at least in part, a result of the introduction of gap junctions,
which allow the intercellular ﬂux of cyclic adenosine monophosphate,
an enhancer of p27Kip1 synthesis. Concomitantly, Cx43 promotes the
degradation of the S phase kinase-associated protein 2, a protein that is
involved in p27Kip1 ubiquitination and degradation. The overall
interplay between these GJIC-dependent and GJIC-independent mech-
anisms results in the accumulation of p27Kip1 and thus in a proliferative
block [33–35]. The exact mechanisms of the channel-independent
actions of connexins on the expression of cell growth and cell death
regulators remain, however, largely unknown. It has been suggested
that connexins can directly affect gene transcription. Connexins, or at
least speciﬁc parts of these molecules, have been reported to reside in
the cell nucleus. Upon its forced expression in human cervical cancer
cells [16], human embryonic kidney cells [16] and mouse neuroblasto-
ma cells [27], the C-terminal tail portion of Cx43 becomes diffusely
located in the cell, including the nucleus, which results in the inhibition
of cell growth. Likewise, human cervical cancer cells transfected with
mutated Cx43, bearing pointmutations in the second extracellular loop,
do not display GJIC because of aberrant cytosolic localization of Cx43,though cell growth is still suppressed [28]. Nonetheless, Omori and
Yamasaki found that mutants of both Cx32 and Cx43, lacking their C-
terminal tail, but not their wild-type counterparts, inhibit cell
proliferation in this same cell type, suggesting that structural regions
other than the C-terminal portion are critical for connexin-mediated
control of cell growth [56]. A potential mechanism by which connexins
could interfere with the expression of tissue homeostasis regulators
implies the existence of connexin-speciﬁc cis-acting gene modules. In
this context, Stains and Civitelli showed the presence of a connexin
response element in the promoter region of the rat osteocalcin gene,
which is controlled by speciﬁcity protein 1 transcription factors. Upon
stimulation of extracellular growth (gap junction-independent primary
response), a yet unidentiﬁed second messenger, possibly inositol
triphosphate, propagates by means of gap junctions (gap junction-
dependent primary response) and subsequently triggers the extracel-
lular regulated kinase and phosphoinositide 3-kinase/protein kinase B
signalling cascades. Activated extracellular regulated kinase then
translocates to the nucleus, where it phosphorylates speciﬁcity protein
1. The latter binds to the connexin response elements, resulting in
osteocalcin gene transcription and thus bone formation [57–59].
Alternatively, the connection between connexins and the production
of cell growth and cell death regulators could also be more indirect and
rely on the interaction between connexins and a number of key tissue
homeostasis determinants. This set of mechanisms will be discussed in
the paragraphs hereafter.3. Interaction of connexins with cell growth and cell death regulators
3.1. β-catenin
In the cell, two pools of β-catenin are found, namely at the
plasma membrane surface, where it serves as a building block for
adherens junctions, and in the cytosol, where it functions as a
regulatory component of the Wingless-Int (Wnt) signalling
pathway. In the absence of Wnt signals, which are secreted
glycoproteins, cytosolic β-catenin forms a complex with the
adenomatous polyposis coli tumour suppressor, axin and glycogen
synthase kinase-3β. This complex phosphorylates β-catenin and
triggers its degradation. Upon the binding of a Wnt ligand to its
receptor at the plasma membrane surface, the degradation
complex becomes destabilised, resulting in cytosolic β-catenin
accumulation. The latter then moves to the nucleus, where it binds
to transcription factors belonging to the family of the T cell
factors/lymphoid enhancer factors. This complex subsequently
activates the transcription of a number of genes encoding G1/S
cell cycle regulators, such as cyclin D1 and c-myc [60–64]. Wnt
signalling also controls the G2/M transition of the cell cycle [65]. It
has been reported that β-catenin interacts with Cx43 at cell–cell
contact areas, and that Cx43 reduces the total amount of β-catenin
that is available for Wnt signalling, thus leading to inhibition of cell
proliferation [66,67]. Furthermore, several genes related to apo-
ptosis, including survivin [68], Bcl-xL [69] and Bcl-2 [70] are
targeted in the Wnt signalling cascade. Interestingly, the Cx43 gene
itself has also been identiﬁed as a downstream target for Wnt
signalling, which suggests that Cx43 can regulate its own
production [66,71]. In fact, activation of the Wnt signalling cascade
by a number of stimuli resulted in increased Cx43 expression and
in some cases, this was associated with enhanced GJIC and
proliferative potential [66,71–81]. Induction of apoptosis in
human osteosarcoma cells with tumour necrosis factor α and
tumour necrosis factor α-related apoptosis-inducing ligand not
only increased Cx43 protein degradation but also augmented the
Cx43 mRNA content. The enhanced Cx43 gene transcription is
thought to represent an adaptive response to apoptosis and is
likely to be mediated by β-catenin [82].
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Despite the acknowledged colocalization of gap junctions with
adherens junctions, the direct interaction between connexins and
cadherins still is a matter of debate [83–87]. Nevertheless, intimate
crosstalk between both cell junction types is critical for their proper
formation, localization and function [75,88–97]. In regenerating mouse
hepatocytes, for instance, the assembly of adherens junctions composed
of E-cadherin, and thus the presence of cell adhesion, is indispensable
for the establishment of Cx32-based gap junctions [98]. Vice versa,
transfection of human liver cancer cells with the Cx26 gene reduces cell
growth, which is associated with induced E-cadherin expression and
thereby the formation of cell adhesion complexes [99,100]. In a similar
way, genetic introduction of Cx43 in human lung cancer cells activates
E-cadherin production and causes a G1/S cell cycle arrest [101]. In
addition, overexpression of N-cadherin and Cx43 in human embryonic
kidney cells synergistically suppresses cell proliferation by prolonging
the G2/M cell cycle transition. This is accompanied by elevated
expression of p21Cip1, which relies on Wnt signalling, and by a
concomitant decline in cyclin-dependent kinase 1 activity [67].
3.3. Zonula occludens 1-associated nucleic acid binding protein
Cx30, Cx32, Cx43 and Cx47 all colocalize with ZO-1-associated
nucleic acid binding protein (ZONAB) in rat brain [102,103]. ZONAB is a
transcription factor that binds to inverted CCAAT-box sequences, found
in the promoter region of genes coding for several cell growth
regulators, including cyclin D1 and the proliferating cell nuclear antigen
[104]. As the name suggests, ZONAB interacts with zonula occludens 1
(ZO-1), a tight junction component. Interaction between ZONAB and
ZO-1, and thus cell growth control, occurs in a cell density-dependent
manner. Indeed, cells grown at low density display low ZONAB–ZO-1
interaction and a high proliferative potential. In these cells, ZONAB
accumulates in the nucleus, where it represses the gene transcription of
human epidermal growth factor receptor 2, a receptor tyrosine kinase
involved in cell growth [105,106]. ZONAB also binds to a number of
other proteins, which may directly or indirectly modulate its transcrip-
tional activity in relation to cell proliferation, including cyclin-
dependent kinase 4 [105,106], ras-related protein [107], heath shock
protein 4A [108], symplekin [109,110] and the guanine nucleotide
exchange factor H1/Lbc's ﬁrst cousin [111].
3.4. Zonula occludens proteins
Apart from the indirect contact via ZONAB, ZO-1 as well as ZO-2
also directly interacts with Cx43. This process is subject to cell cycle
phase-speciﬁc control. Thus, Cx43 has a strong binding preference for
ZO-1 during the G0 phase, whereas Cx43–ZO-2 interaction occurs
equally during the G0 phase and the S phase in rat kidney epithelial
cells [112]. Similar to ZO-1, ZO-2 binds to transcription factors, in casu
c-jun, c-fos and CCAAT enhancer binding protein [113], and thereby
shuttles between the cell periphery and the nucleus [114–116]. As
such, ZO-2 was found to downregulate cyclin D1 gene transcription
[116,117], to increase cyclin D1 protein degradation [116], and
ultimately to inhibit cell cycling at the G0/G1 transition [116].
3.5. Nephroblastoma overexpressed protein
Ectopic expression of Cx43 in glioma cells increases GJIC and
decreases cell growth in vitro and in vivo, coinciding with elevated
expression of the cysteine rich 61 protein and the nephroblastoma
overexpressed (NOV) protein. The latter colocalizes with Cx43 gap
junction plaques at the plasma membrane surface [118–121]. It has
indeed been shown that NOV interacts with Cx43, but not with other
connexins, includingCx32 andCx40, in glioma cells and choriocarcinoma
cells [122–124]. NOV is amember of the CCN family,which is an acronymfor cysteine rich 61, connective tissue growth factor and NOV. CCN
proteins aremultimodular regulators known to play roles in a number of
biological processes [125]. NOV itself is involved in cell cycle control and
inhibits proliferation. It is believed that Cx43 is able to regulate cell
growth by increasing NOV production, the concomitant shift of NOV
localization from the nucleus to the plasma membrane surface and the
direct binding of NOV to Cx43 [122–124].
3.6. Discs-Large homolog 1 protein
In hepatocytes, Cx32 interacts with the scaffolding protein Dlgh1
(Discs-Large homolog 1). Dlgh1 acts as a tumour suppressor protein
and its presence at the plasma membrane surface, bound to Cx32, is
associated with a cell cycle block at the G0/G1 transition. Upon its
release, occurring following downregulation of Cx32 expression,
Dlgh1 translocates to the cell nucleus, where its actions lead to
increased proliferative activity. Therefore, maintaining Dlgh1 at the
plasma membrane surface may be a regulatory mechanism by which
Cx32 controls hepatocyte proliferation [126].
3.7. B-cell lymphoma-2 proteins
The B-cell lymphoma-2 family comprises a number of proteins that
are involved in the control of apoptosis, particularly in the intrinsic
pathway. They can either promote (e.g. Bax and Bak) or suppress (e.g.
Bcl-2 and Bcl-xL) the apoptotic process by affecting cytochrome C
release frommitochondria. In humanbreast cancer cells, Cx26 and Cx43
were reported to colocalizewith Bak, but not with Bcl-2 [127]. Likewise,
Cx26 showed aberrant cytoplasmic staining in human colorectal cells,
where it was associated with Bcl-xL and Bax [128]. These ﬁndings
suggest that connexins participate in cell death pathways throughdirect
interaction with apoptotic factors.
3.8. Apoptosis signal-regulating kinase 1
Apoptosis signal-regulating kinase 1 (ASK1) is an upstream
activator of c-jun N-terminal kinases that plays a central role in
oxidative stress-related cellular insults and apoptosis. Cx43 has been
demonstrated to directly interact with ASK1, which results in
protection against apoptosis induced by hydrogen peroxide in Cx43-
overexpressing rat glioma cells. ASK1 activity is regulated by many
kinases. On the other hand, Cx43 is known to interact with a plethora
of kinases. Therefore, Cx43 could indirectly alter the phosphorylation
status of ASK1, which provides resistance to cell death following
oxidative challenge [129].
4. Conclusions and perspectives
Connexins and their channels are essentially involved in cell
growth and cell death control by acting at three cellular communica-
tive levels. At the intercellular level, GJIC foresees the direct exchange
of tissue homeostasis determinants betweenneighbouring cells. At the
extracellular level, hemichannels allow the paracrine release of tissue
homeostasis regulatory proteins. At the intracellular level, and as
outlined in the current paper, connexin proteins can directly or
indirectly affect the production of cell growth and cell death regulators
or can act as a cellular signalling reservoir by reversibly interacting
with these substances (Fig. 1) [7,13,130]. The latter type of connexin-
related signalling is actually reminiscent of other cell junction
proteins, such as the adherens junction protein β-catenin [60–64]
and the tight junction building blocks ZO-1/2 [112–116] and ZONAB
[104–106], which also individually affect tissue homeostasis by
mechanisms that exceed their function as cell junction building
stones. Thus far, the non-channel functions of connexins in the
management of the cellular life cycle have beenmainly revealed rather
coincidentally, i.e. in experiments wherein connexin expression is
Fig. 1. Non-channels functions of connexins in cell growth and cell death. Connexin proteins can affect tissue homeostasis independently of their channel properties by altering the
expression of tissue homeostasis determinants and by direct interaction with cell growth and cell death regulators. Thus, connexins (e.g. Cx32 and Cx43) colocalize with cadherins
(e.g. E-cadherin and N-cadherin) that maintain cell adhesion, which in turn favours cell growth arrest (1). Cx43 also interacts with another adherens junction building stone, namely
β-catenin, a critical component of the Wnt signalling cascade known to regulate the expression of cell growth and cell death regulators (2). Furthermore, connexins (i.e. Cx43) bind
to the tight junction components ZO-1 (3) and ZO-2 (4) that interact with transcription factors, such as ZONAB and c-jun, respectively, known to control the gene transcription of
regulators of tissue homeostasis. In addition, Cx43 and Cx32 bind to NOV (5) and Dlgh1 (6), respectively, that both inﬂuence cell cycling. Connexin proteins, particularly Cx43, can
promote the degradation of the Skp2 protein, resulting in intracellular accumulation of p27Kip1 and a proliferative arrest (7), and can interact with B-cell lymphoma-2 proteins and
ASK1, thereby affecting apoptotic activity (8). (ASK1, apoptosis signal-regulating kinase 1; Cx, connexin; Dlgh1, Discs-Large homolog 1; NOV, nephroblastoma overexpressed; Skp2,
S phase kinase-associated protein 2; TCF/LEF; T cell factors/lymphoid enhancer factor; ZO-1/2, zonula occludens 1/2; ZONAB, ZO-1-associated nucleic acid binding protein).
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attention. Hence, this research ﬁeld is largely in its infancy and very
few reports have shed light onto themolecular mechanisms that drive
such atypical cellular functions of connexins. Furthermore, this area
has been complicated by the discovery of pannexins, a set of connexin-
like proteins that consists of at least three members in rodents and
man. Pannexins assemble in hexameric hemichannels, rather than in a
gap junction conﬁguration. Similar to their connexin counterparts,
pannexin hemichannels allow thepassiveﬂux of smallmolecules, such
as adenosine triphosphate, between the cytosol and the extracellular
environment [8,131,132]. Besides acting as channel entities, pannex-
ins can also impact tissue homeostasis by non-channel mechanisms, a
feature that has been recently reviewed in the context of cell growth
[13] and cell death [7]. While studying the latter two processes,
discriminating between molecular actions related to either connexins
or pannexins has been, and still is, a major challenge [133]. With the
introduction of novel tools that allow to speciﬁcally affect the
expression of individual connexins and pannexins, such as RNA
interference approaches, such constraints will be overcome. It istherefore expected that this research ﬁeld, in casu in the light of cell
growth and cell death regulation, will experience a true boost in the
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